HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Imatinib therapy in a patient with suspected chronic neutrophilic leukemia and FIP1L1-PDGFRA rearrangement.

AuthorsNitin Jain, Joseph D Khoury, Naveen Pemmaraju, Praveen Kollipara, Hagop Kantarjian, Srdan Verstovsek
JournalBlood (Blood) Vol. 122 Issue 19 Pg. 3387-8 (Nov 07 2013) ISSN: 1528-0020 [Electronic] United States
PMID24203930 (Publication Type: Case Reports, Letter)
Chemical References
  • Antineoplastic Agents
  • Benzamides
  • Oncogene Proteins, Fusion
  • Piperazines
  • Pyrimidines
  • mRNA Cleavage and Polyadenylation Factors
  • Imatinib Mesylate
  • FIP1L1-PDGFRA fusion protein, human
  • Receptor, Platelet-Derived Growth Factor alpha
Topics
  • Antineoplastic Agents (therapeutic use)
  • Benzamides (therapeutic use)
  • Humans
  • Imatinib Mesylate
  • Leukemia, Neutrophilic, Chronic (diagnosis, drug therapy, genetics)
  • Male
  • Middle Aged
  • Mutation
  • Oncogene Proteins, Fusion (genetics)
  • Piperazines (therapeutic use)
  • Pyrimidines (therapeutic use)
  • Receptor, Platelet-Derived Growth Factor alpha (genetics)
  • Treatment Outcome
  • mRNA Cleavage and Polyadenylation Factors (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: